Back to School: How biopharma can reboot drug development. Access exclusive analysis here

JNJ beats Street

Johnson & Johnson (JNJ) posted second quarter EPS of $0.82, beating the Street consensus by $0.03 and up

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE